演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

Helical tomotherapy for the treatment of stage I non-small cell lung cancer

演題番号 : ISP-24

[筆頭演者]
Yukihiro Hama:1 

1:Edogawa Hospital, Japan

 

[PURPOSE] The purpose of this study was to evaluate the feasibility and safety of helical tomotherapy-based stereotactic ablative radiotherapy (SABR) for medically inoperable stage I non-small cell lung cancer. [METHOD AND MATERIALS] Between May 2011 and December 2012, 10 patients with medically inoperable stage I non-small cell lung cancer were prospectively enrolled. Helical tomotherapy-based SABR treatment plans were generated for a median dose of 60 Gy/5 fractions/1 week (range 50-60 Gy/5-10 fxs). Acute and late toxicities were recorded every day during radiotherapy and every 3 months thereafter. Chest CT scans were scheduled 1 month after completing radiotherapy and every 3 months thereafter. Toxicity was scored using Common Terminology Criteria for Adverse Events version 4.0. [RESULTS] Median follow-up time for all patients was 9 (range: 3-21) months. No patient developed a local recurrence during follow-up. Two patients developed distant metastases outside the PTV. Two patients showed focal and peripheral fibrosis on CT scans. But, no patient experienced acute or late Grade 2 or higher toxicity. [CONCLUSION] Helical tomotherapy-based SABR is feasible for medically inoperable patients with stage I non-small cell lung cancer.

前へ戻る